ArticleAntimicrobial agents and chemotherapy2026
A monoclonal antibody targeting OXA23 restores carbapenem susceptibility in global epidemic carbapenem-resistant
Mingxi Hua, Hengkun Wei, Yu Jiang, Chaoyang Gu, Yu Cao, Jinglin Yue, Yumin Meng, Jingyuan Liu, Hui Zeng, Chen Chen
Abstract read
In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Mingxi Hua *Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-2525-6822 Hengkun Wei *Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yu JiangBiomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Chaoyang GuBiomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yu CaoBiomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Jinglin YueBiomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-0299-7209 Yumin MengLaboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Jingyuan Liu *Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-0592-9789 Hui Zeng *Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-7456-6061 Chen Chen *Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-1765-8899 Funding
Beijing Clinical Key Specialty Construction Project (Intensive Care Medicine), Beijing Ditan HospitalBeijing Municipal Natural Science Foundation 7252073
6 · The paper itselfAbstract
Indexed as
Acinetobacter baumanniiAnti-Bacterial AgentsAntibodies, Monoclonalbeta-LactamasesCarbapenemsAcinetobacter InfectionsAnimalsHumansMeropenemMicrobial Sensitivity TestsAnti-Bacterial AgentsAntibodies, Monoclonalbeta-lactamase OXA-23beta-LactamasesCarbapenemsMeropenemAcinetobacter baumanniiantibodybacterial infectioncarbapenem resistanceOXA23
Identifiers
PMID42376991
PMCPMC13436263
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390